Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05318937 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT05318937 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT05318937, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Interventions
- DRUG SAGE-718
- DRUG SAGE-718-matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-06-06 |
| Est. Completion | 2024-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05318937
The ClinicalTrials.gov registry entry for NCT05318937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAGE-718 is the first listed.
NCT05318937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05318937 about?
NCT05318937 is a clinical study titled "A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment". The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
What is the current status of trial NCT05318937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-06-06. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT05318937?
The interventions under investigation include: SAGE-718 (DRUG), SAGE-718-matching placebo (DRUG).
Who is sponsoring clinical trial NCT05318937?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.